DGAP-News: BLACKHAWK GROWTHS MINDBIO THERAPETUICS PLANS TO COMMERVIALIZE INTELLECTUAL PROPERTY GENERATED FROM UNIVERSITY OF AUCKLAND CLINICAL TRIAL IN PSYCHEDELIC THERAPY IN ADVANCED STAGE CANCER PATIENTS
- 26
DGAP-News: Blackhawk Growth Corp.
/ Key word(s): Strategic Company Decision/Study
Vancouver, British Columbia - September 16, 2021 - Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the "Company" or "Blackhawk") is pleased to provide an update on MindBio Therapeutics Pty Ltd. ("MindBio Therapeutics"), a clinical stage drug development company conducting research into microdosing and medicinal use of psychedelic medicine. MindBio Theraepeutics plans to commercialize the intellectual property generated from the University of Auckland clinical trial in psychedelic assisted therapy in advanced-stage cancer patients. The administration of high-dose psychedelic compounds has shown clinically significant benefits in the treatment of psychological distress in advanced cancer patients. However, psychedelics at high doses can vividly alter perceptions; an experience that poses challenges in this vulnerable population. 'Microdosing' - repeated administration of psychedelics in low doses does not alter perceptions but may offer similar benefit in reducing anxiety, depression and existential distress. This study will evaluate the feasibility of conducting a randomised controlled trial comparing psychedelic-microdose assisted in people who have advanced cancer, anxiety or depression. Participants will be randomised to receive psychotherapy alongside doses of either an LSD microdose or placebo. The feasibility, acceptability, safety and potential psychological benefits of this intervention will be assessed. The findings will inform the development of a larger trial and provide initial indication of potential benefits of psychedelic microdosing in advanced cancer. About Blackhawk Growth The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A Please join the conversation on our Blackhawk group supporter's telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com. For further information please contact: (403)-991-7737 Cautionary Note Regarding Forward-Looking Statement
16.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Blackhawk Growth Corp. |
Canada | |
ISIN: | CA09238B3083 |
WKN: | A2QJN3 |
EQS News ID: | 1233798 |
End of News | DGAP News Service |
|
1233798 16.09.2021
EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.
- UAB Partnerystės projektai keturi 2023 audited annual report
- Ørsted to present Q1 2024 results on 2 May
- EQS-News: Asklepios Group: Asklepios shows resilience in 2023 financial year
- EQS-News: Nabaltec AG with a dividend proposal of EUR 0.28 per share and revenues of EUR 54.0 million in the first quarter of 2024 according to preliminary figures
- Share Buyback Transaction Details April 18 – April 24, 2024
- Trakx launches a new product: Trakx USDc Earn CTI powered by OpenTrade